A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)

NCT04234607 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

738

Enrollment

INDUSTRY

Sponsor class

Conditions

Extensive Small Cell Lung Cancer

Interventions

DRUG: TQB2450
DRUG: Anlotinib
DRUG: Etoposide
DRUG: Carboplatin
DRUG: TQB2450（blank）
DRUG: Anlotinib（blank)

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.